Brokerages expect Syneos Health Inc (NASDAQ:SYNH) to announce $0.83 earnings per share for the current fiscal quarter, Zacks reports. Six analysts have provided estimates for Syneos Health’s earnings, with the highest EPS estimate coming in at $0.84 and the lowest estimate coming in at $0.82. Syneos Health posted earnings of $0.75 per share in the same quarter last year, which suggests a positive year-over-year growth rate of 10.7%. The business is scheduled to issue its next earnings results before the market opens on Thursday, October 31st.
According to Zacks, analysts expect that Syneos Health will report full-year earnings of $3.17 per share for the current fiscal year, with EPS estimates ranging from $3.15 to $3.18. For the next fiscal year, analysts forecast that the company will report earnings of $3.64 per share, with EPS estimates ranging from $3.54 to $3.71. Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side research firms that follow Syneos Health.
Syneos Health (NASDAQ:SYNH) last released its quarterly earnings results on Tuesday, August 6th. The company reported $0.61 EPS for the quarter, topping analysts’ consensus estimates of $0.59 by $0.02. Syneos Health had a net margin of 0.36% and a return on equity of 9.82%. The firm had revenue of $1.17 billion during the quarter, compared to analysts’ expectations of $1.15 billion. During the same period in the previous year, the company earned $0.62 EPS. The firm’s revenue for the quarter was up 8.8% compared to the same quarter last year.
Several institutional investors and hedge funds have recently modified their holdings of the company. Boston Advisors LLC acquired a new stake in shares of Syneos Health in the 2nd quarter worth $1,257,000. BB&T Corp increased its position in Syneos Health by 8.1% during the 2nd quarter. BB&T Corp now owns 8,749 shares of the company’s stock valued at $448,000 after buying an additional 656 shares in the last quarter. Tiverton Asset Management LLC acquired a new position in Syneos Health during the 2nd quarter valued at about $279,000. Holocene Advisors LP increased its position in Syneos Health by 19.9% during the 2nd quarter. Holocene Advisors LP now owns 131,140 shares of the company’s stock valued at $6,700,000 after buying an additional 21,746 shares in the last quarter. Finally, Parametric Portfolio Associates LLC raised its stake in Syneos Health by 18.8% in the second quarter. Parametric Portfolio Associates LLC now owns 301,841 shares of the company’s stock valued at $15,421,000 after buying an additional 47,822 shares during the last quarter.
Syneos Health stock traded down $0.54 during midday trading on Tuesday, reaching $53.23. The stock had a trading volume of 327,700 shares, compared to its average volume of 351,344. The company has a quick ratio of 0.89, a current ratio of 0.89 and a debt-to-equity ratio of 0.99. The firm has a market cap of $5.56 billion, a price-to-earnings ratio of 20.32, a price-to-earnings-growth ratio of 1.88 and a beta of 1.51. Syneos Health has a 52-week low of $36.26 and a 52-week high of $56.34. The company has a fifty day moving average of $53.84 and a 200 day moving average of $49.40.
About Syneos Health
Syneos Health, Inc operates as an integrated biopharmaceutical solutions company in North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates through two segments, Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers various clinical development services spanning Phase I to Phase IV, including full-service global studies, as well as clinical monitoring, investigator recruitment, patient recruitment, data management, and study startup to assist customers with drug development process.
Recommended Story: How to calculate the intrinsic value of a stock
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Syneos Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syneos Health and related companies with MarketBeat.com's FREE daily email newsletter.